Crosstalk of the heart and periphery: skeletal and cardiac muscle as therapeutic targets in heart failure.
Heart failure syndrome is initiated as the body's metabolic needs temporarily exceed the pumping capacity of the heart. In most cases, this phenomenon tends to occur during physical exercise. Although not always subjectively recognized, limited exercise capacity remains the clinical hallmark of congestive heart failure. It can be measured objectively as reduced skeletal muscle performance and maximal whole-body oxygen uptake, which are not necessarily explained by central haemodynamic abnormalities. In fact, the initial cardiac condition sets forth a series of peripheral adaptations that are potentially life-saving during acute decompensation but become disadvantageous and symptom-generating in stable heart failure. Inodilator drugs were theoretically ideal to revert the adverse haemodynamic crosstalk between the heart and periphery. However, these drugs failed to improve prognosis in congestive heart failure, whereas drugs that did so showed typically unimpressive haemodynamic effects. Exercise therapy has recently emerged as a safe and effective way to enhance physical performance and subjective well-being in congestive heart failure. A dual therapeutic approach is suggested, consisting of exercise training to improve the periphery and the use of cardioprotective drugs to limit cardiac cellular damage from neurohormonal activation.
Gordon
A
A
Department of Cardiology, Karolinska Institute, Huddinge Hospital, Sweden.
Voipio-Pulkki
L M
LM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D002302:Cardiac Output; D002316:Cardiotonic Agents / Q000627:therapeutic use; D000077261:Carvedilol; D005081:Exercise Therapy; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009130:Muscle, Smooth / Q000502:physiology*; D011412:Propanolamines / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D016277:Ventricular Function, Left
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D002316:Cardiotonic Agents; D011412:Propanolamines; D014665:Vasodilator Agents; D000077261:Carvedilol